Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma
Table 2
Baseline tumor characteristics.
Characteristic
All cohort
Outside Milan criteria
Inside Milan criteria
value
Unfavorable response
Favorable response
value
Time from Pre-Y90-RE imaging to Y90-RE, mean months
2.3 ± 1.7
2.3 ± 1.1
69 ± 67
0.9
2.5 ± 1.3
2.1 ± 1.9
0.2
Method of diagnosis, imaging
116 (86%)
63 (83%)
53 (91%)
0.1
40 (74%)
76 (94%)
0.003
Hepatic cirrhosis
119 (88%)
66 (87%)
53 (90%)
0.4
46 (85%)
73 (90%)
0.3
Affected hepatic lobe
Right lobe
75 (55%)
6 (8%)
18 (31%)
0.03
3 (6%)
21 (26%)
0.06
Left lobe
24 (18%)
37 (49%)
38 (64%)
23 (43%)
52 (64%)
Both lobes (multilobar)
36 (27%)
33 (43%)
3 (5%)
28 (52%)
8 (10%)
Tumor characteristics
Largest tumor diameter, mean (mm)
39 ± 17
44 ± 18
31 ± 12
≤0.0001
44 ± 18
35 ± 15
0.006
2nd largest tumor diameter, mean (mm)
21 ± 10
22 ± 10
11 ± 6
0.1
22 ± 10
20 ± 10
0.3
3rd largest tumor diameter, mean (mm)
15 ± 6
15 ± 6
8 ± 3
0.06
15 ± 6
13 ± 5
0.2
Total tumor cumulative diameter, mean (mm)
54 ± 29
72 ± 27
32 ± 12
≤0.0001
70 ± 30
44 ± 23
0.0001
Patients with ≥4 HCC masses
28 (21%)
28 (37%)
0 (0%)
≤0.0001
23 (43%)
5 (6%)
0.0001
Post Y90-RE tumor characteristics
mRECIST response
Complete response
56 (42%)
14 (18%)
42 (71%)
≤0.0001
3 (6%)
53 (65%)
0.0001
Partial response
30 (22%)
22 (29%)
8 (14%)
10 (19%)
20 (25%)
Stable disease
34 (25%)
30 (39%)
4 (7%)
26 (48%)
8 (10%)
Progression of disease
15 (11%)
10 (13%)
5 (8%)
15 (28%)
0 (0%)
Tumor characteristics
Largest tumor diameter, mean (mm)
38 ± 26
41 ± 26
27 ± 20
0.02
44 ± 18
35 ± 15
0.006
2nd largest tumor diameter, mean (mm)
22 ± 11
23 ± 11
15 ± 5
0.01
22 ± 10
20 ± 10
0.4
3rd largest tumor diameter, mean (mm)
15 ± 8
15 ± 7
12 ± 8
0.6
15 ± 6
13 ± 5
0.2
Total tumor cumulative diameter, mean (mm)
34 ± 41
53 ± 43
10 ± 22
≤0.0001
70 ± 30
44 ± 23
≤0.0001
Patients with ≥4 HCC masses
24 (18%)
21 (28%)
3 (5%)
0.0004
23 (43%)
5 (6%)
≤0.0001
The symbol indicates a significant value. MC = Milan criteria; ECOG = Eastern Cooperative Oncology Group; ALBI = albumin-bilirubin; BCLC = Barcelona Clinic Liver Cancer.
